Alnylam Pharmaceuticals, Inc. (ALNY) Revenue by Segment
Alnylam Pharmaceuticals revenue by segment at a glance
In Q2 fiscal 2026 (the quarter ended June 30, 2026), Alnylam Pharmaceuticals's largest product or service was Amvuttra, with $1.01 billion or 78% of revenue, up 105.7% from a year earlier. Next: Givlaari (7%), Royalty (6%) and Oxlumo (4%).
The fastest-growing product or service from a year earlier was Amvuttra (+105.7%).
From company filings, in USD; latest quarter ended June 30, 2026; quarterly data from Q1 fiscal 2019.
Alnylam Pharmaceuticals, Inc.
ALNY
Healthcare
Revenue breakdown
Fiscal quarters, from company filings
Alnylam Pharmaceuticals revenue by product or service, last 4 quarters
| Product or service | Q2 FY26 | Q1 FY26 | Q3 FY25 | Q2 FY25 | Share |
|---|---|---|---|---|---|
| Amvuttra | $1.0B | $889.9M | $685.3M | $492.0M | 78% |
| Givlaari | $89.8M | $74.4M | $73.9M | $80.8M | 7% |
| Royalty | $71.7M | $49.0M | $46.2M | $40.0M | 6% |
| Oxlumo | $52.1M | $51.3M | $52.8M | $46.9M | 4% |
| Collaborations | $47.2M | $82.1M | $351.7M | $61.5M | 4% |
| Onpattro | $18.5M | $20.5M | $39.1M | $52.5M | 1% |
In USD, fiscal quarters as reported; share = part of Q2 FY26 revenue.
Questions and answers
Which product or service makes the most money for Alnylam Pharmaceuticals?
Amvuttra: $1.01 billion, or 78% of revenue, in Q2 fiscal 2026.
What are Alnylam Pharmaceuticals's main products and services?
By revenue in Q2 fiscal 2026: Amvuttra (78%), Givlaari (7%), Royalty (6%) and Oxlumo (4%).
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.
